Home/Pipeline/PAH Program

PAH Program

Pulmonary Arterial Hypertension

Phase 2bCompleted

Key Facts

Indication

Pulmonary Arterial Hypertension

Phase

Phase 2b

Status

Completed

Company

Insmed

About Insmed

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform lives of patients facing serious diseases. The company has achieved commercial success with approved therapies in the US and EU, while advancing multiple programs through clinical development. Insmed has been consistently recognized as Science magazine's #1 Top Biopharma Employer for five consecutive years and maintains a culture of collaboration and innovation across 9 corporate offices worldwide.

View full company profile

Therapeutic Areas

Respiratory Diseases Rare Diseases Pulmonary Arterial Hypertension Bronchiectasis Interstitial Lung Disease

Other Pulmonary Arterial Hypertension Drugs

Drug	Company	Phase	Status
GSK3640254	GSK plc	Phase 2	Active
Treprostinil (Remodulin)	United Therapeutics	Commercial	Approved
Treprostinil (Orenitram)	United Therapeutics	Commercial	Approved
Selexipag (Uptravi)	United Therapeutics	Commercial	Approved
Ralinepag	United Therapeutics	Phase 3	Active
Orenitram®	Supernus Pharmaceuticals	Approved/Commercial	Developed for United Therapeutics
Tadliq® (Tadalafil Oral Suspension)	CMP Pharma	Approved	Marketed